Showing results (111-120 of 247) with videos related to

Sort By:
Pageof 25
Proceedings of the National Academy of Sciences of the United States of America|March 2, 2005
Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitorsMelissa J Peart, Gordon K Smyth, Ryan K van Laar, et al.
Blood|December 19, 2013
Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cellsToshihiko Tanno, Yiting Lim, Qiuju Wang, et al.
RSC Medicinal Chemistry|April 25, 2025
VHL-independent degradation of hepatitis B virus e antigen (HBeAg) by VHL-binding chimeric small moleculesLiam T Hales, Simon J Mountford, Mina Takawy, et al.
Clinical Epigenetics|January 28, 2023
A phase 1 clinical trial of the repurposable acetyllysine mimetic, n-methyl-2-pyrrolidone (NMP), in relapsed or refractory multiple myelomaJake Shortt, Peter Galettis, Chan Y Cheah, et al.
Nature Communications|March 7, 2017
Genomic characterisation of Eμ-Myc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor geneMarcus Lefebure, Richard W Tothill, Elizabeth Kruse, et al.
Internal Medicine Journal|November 27, 2022
Low mortality in vaccinated immunocompromised haematology patients infected with SARS-CoV-2Briony Shaw, Jake Shortt, Michael Low, et al.
Internal Medicine Journal|July 2, 2020
Excellent outcomes of transformed lymphomas in the rituximab era without autologous stem cell transplantation: an Australian single-centre experienceAditya Tedjaseputra, Michael Gilbertson, Michael Low, et al.
British Journal of Haematology|June 26, 2023
A sequential cohort study evaluating single-agent KappaMab and KappaMab combined with lenalidomide and low-dose dexamethasone in relapsed and/or refractory kappa light chain-restricted multiple myeloma (AMaRC 01-16)Andrew Spencer, Anna Kalff, Jake Shortt, et al.
Epigenomics|November 8, 2012
A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®))Simon J Harrison, Mark Bishton, Susan E Bates, et al.
Haematologica|July 4, 2007
Blood transfusion requirements for patients undergoing chemotherapy for acute myeloid leukemia how much is enough?Mark A Dawson, Sharon Avery, Zoe K McQuilten, et al.
Pageof 25